2011•European Journal of CancerRequires access

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial

J. Baselqa, Mario Campone, Tarek Sahmoud, M. Piccart, H. Burris, Hope Rugo, S Noguchi, Michael Gnant, Pabak Mukhopadhyay, G. N. Hortobagyi

Open publisher page 19 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Exemestane, Anastrozole, Letrozole, Medicine, Everolimus, Oncology, Refractory (planetary science), Postmenopausal women

Back to paper search Browse research topics Original source

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial — Research Paper | ScholarLens